New Guidelines for the Management of Hypertrophic Cardiomyopathy

An important consensus document on a potentially fatal disorder that, while often clinically silent, is increasingly identified

Sponsoring Organizations: American College of Cardiology, American Heart Association, American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons

Background and Purpose: Development of these guidelines was impelled by the relatively high prevalence of hypertrophic cardiomyopathy (HCM) in the general population and the perceived lack of consensus regarding many aspects of its management, including the utility of genetic testing, the emergence of two different techniques for septal reduction therapy, and the role of implantable cardioverter-de…

Reviewing Author

Frederick A. Masoudi, MD, MSPH, FACC, FAHA

Disclosures

Consultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research

Grant/Research SupportNational Heart, Lung, and Blood Institute

Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)

Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)

Frederick A. Masoudi, MD, MSPH, FACC, FAHA

Disclosures

Consultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research

Grant/Research SupportNational Heart, Lung, and Blood Institute

Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)

Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)